Anika Therapeutics Inc. (ANIK)
14.84
-0.27 (-1.79%)
At close: Mar 31, 2025, 12:22 PM
Anika Therapeutics Inc. Revenue Breakdown
Quarter | Sep 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Joint Preservation and Restoration Revenue | 11.95M | 13.84M | 15.3M | 13.47M | 12.66M | 13.45M | 14.35M | 11.82M | 12.1M | 12.14M | 13.29M | 11.19M | 11.88M | 12.22M |
Joint Preservation and Restoration Revenue Growth | -13.66% | -9.51% | +13.56% | +6.40% | -5.89% | -6.23% | +21.37% | -2.27% | -0.36% | -8.67% | +18.75% | -5.81% | -2.74% | n/a |
Non-Orthopedic Revenue | 2.38M | 2.36M | 2.6M | 3.11M | 2.31M | 1.84M | 1.53M | 2.78M | 1.82M | 1.82M | n/a | n/a | n/a | n/a |
Non-Orthopedic Revenue Growth | +0.47% | -9.18% | -16.22% | +34.62% | +25.57% | +20.37% | -45.03% | +52.55% | 0.00% | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
Quarter | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|
Europe Revenue | 21.72M | 20.64M | 19.58M | 14.18M | 14.74M | 11.73M | 12.44M | 10.95M | 8.76M | 6.21M | 6.27M |
Europe Revenue Growth | +5.26% | +5.41% | +38.09% | -3.83% | +25.69% | -5.67% | +13.53% | +25.09% | +40.90% | -0.85% | n/a |
United States Revenue | 123.13M | 119.15M | 113.83M | 103.18M | 90.3M | 85.35M | 92.91M | 83.97M | 76.62M | n/a | n/a |
United States Revenue Growth | +3.34% | +4.67% | +10.32% | +14.26% | +5.80% | -8.13% | +10.64% | +9.59% | n/a | n/a | n/a |
Operating Expense Breakdown
Quarter | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selling, General, and Administrative Revenue | 19.11M | 19.81M | 21.53M | 20.34M | 24.83M | 23.69M | 27M | 23.05M | 21.28M | 21.27M | 19.2M | 20.43M | 17.5M | 17.99M | 18.18M | 15.18M | 15.9M | 14.55M | 14.43M | 12.24M | 7.54M | 7.5M | 7.67M | 6.13M | 5.7M | 6.42M | 16.09M | 6.68M | 4.82M | 4.97M | 5.07M | 5.49M | 4.28M | 4.25M | 3.99M | 4.52M | 3.31M | 3.39M | 3.6M |
Selling, General, and Administrative Revenue Growth | -3.50% | -7.99% | +5.86% | -18.09% | +4.80% | -12.25% | +17.12% | +8.33% | +0.04% | +10.77% | -6.02% | +16.75% | -2.72% | -1.02% | +19.74% | -4.55% | +9.30% | +0.82% | +17.93% | +62.32% | +0.49% | -2.22% | +25.18% | +7.53% | -11.17% | -60.12% | +140.94% | +38.46% | -3.00% | -1.87% | -7.67% | +28.22% | +0.59% | +6.64% | -11.80% | +36.73% | -2.35% | -6.00% | n/a |
Research and Development Revenue | 7.24M | 7.4M | 8.16M | 7.58M | 7.79M | 8.91M | 8.4M | 7.75M | 7.3M | 6.97M | 6.16M | 6M | 7.67M | 7.29M | 6.36M | 7.63M | 5.22M | 4.53M | 6.05M | 4.08M | 4.16M | 4.17M | 4.26M | 4.06M | 4.23M | 4.73M | 5.16M | 4.27M | 5.84M | 4.45M | 4.23M | 2.96M | 2.82M | 2.79M | 2.16M | 3.02M | 2.06M | 1.81M | 2.1M |
Research and Development Revenue Growth | -2.08% | -9.38% | +7.63% | -2.64% | -12.60% | +6.12% | +8.40% | +6.14% | +4.67% | +13.29% | +2.62% | -21.80% | +5.21% | +14.65% | -16.65% | +46.29% | +15.11% | -25.09% | +48.14% | -1.78% | -0.17% | -2.18% | +4.77% | -3.97% | -10.59% | -8.29% | +20.98% | -26.98% | +31.31% | +5.18% | +42.95% | +4.85% | +1.07% | +29.32% | -28.42% | +46.29% | +13.76% | -13.61% | n/a |